metformin has been researched along with Brain Vascular Disorders in 7 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " A low prevalence of AD in patients with T2D was associated with residency in urban areas, the comorbidity of hemiplegia or paraplegia, the usage of metformin and sulfonylureas, and rapid-acting insulin injection therapy." | 3.85 | Prevalence of anxiety disorder in patients with type 2 diabetes: a nationwide population-based study in Taiwan 2000-2010. ( Hsieh, HM; Huang, CJ; Jiang, HJ; Lin, CH; Tu, HP; Wang, PW, 2017) |
| "We enrolled type 2 diabetes patients who received DPP4i or SU in addition to metformin." | 1.72 | Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes. ( Chien, KL; Wang, J; Wu, HY, 2022) |
| "no comorbidities) but more likely in congestive heart failure (OR 1." | 1.56 | Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed? ( Bell, JS; Ilomäki, J; Keen, CS; Magliano, DJ; Shaw, JE; Wood, SJ, 2020) |
| "To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2 diabetes from a population-based cohort." | 1.51 | Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study. ( An, JH; Bae, JH; Baik, SH; Choi, J; Choi, KM; Kim, HY; Kim, KJ; Kim, NH; Kim, SG; Lee, J; Seo, JA; Yoo, HJ, 2019) |
| "Metformin is recommended in type 2 diabetes mellitus because it reduced mortality among overweight participants in the United Kingdom Prospective Diabetes Study when used mainly as a means of primary prevention." | 1.36 | Metformin use and mortality among patients with diabetes and atherothrombosis. ( Bhatt, DL; Goto, S; Marre, M; Pasquet, B; Porath, A; Ravaud, P; Roussel, R; Smith, SC; Steg, PG; Travert, F; Wilson, PW, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Wu, HY | 1 |
| Chien, KL | 1 |
| Wood, SJ | 1 |
| Magliano, DJ | 1 |
| Bell, JS | 1 |
| Shaw, JE | 1 |
| Keen, CS | 1 |
| Ilomäki, J | 1 |
| Kim, KJ | 1 |
| Choi, J | 1 |
| Lee, J | 1 |
| Bae, JH | 1 |
| An, JH | 1 |
| Kim, HY | 1 |
| Yoo, HJ | 1 |
| Seo, JA | 1 |
| Kim, NH | 2 |
| Choi, KM | 1 |
| Baik, SH | 1 |
| Kim, SG | 1 |
| Tu, HP | 1 |
| Lin, CH | 1 |
| Hsieh, HM | 1 |
| Jiang, HJ | 1 |
| Wang, PW | 1 |
| Huang, CJ | 1 |
| Roussel, R | 1 |
| Travert, F | 1 |
| Pasquet, B | 1 |
| Wilson, PW | 1 |
| Smith, SC | 1 |
| Goto, S | 1 |
| Ravaud, P | 1 |
| Marre, M | 1 |
| Porath, A | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Eurich, DT | 1 |
| Majumdar, SR | 1 |
| McAlister, FA | 1 |
| Tsuyuki, RT | 1 |
| Johnson, JA | 1 |
| Katayama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Brain Vascular Disorders
| Article | Year |
|---|---|
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
6 other studies available for metformin and Brain Vascular Disorders
| Article | Year |
|---|---|
Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
Topics: Cerebrovascular Disorders; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibi | 2022 |
Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Australia; Cerebrovascular Disorders; Comorbidity; Diab | 2020 |
Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Topics: Biomarkers; Blood Glucose; Cerebrovascular Disorders; Databases, Factual; Diabetes Mellitus, Type 2; | 2019 |
Prevalence of anxiety disorder in patients with type 2 diabetes: a nationwide population-based study in Taiwan 2000-2010.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anxiety Disorders; Cerebrovascular Dis | 2017 |
Metformin use and mortality among patients with diabetes and atherothrombosis.
Topics: Age Factors; Aged; Aged, 80 and over; Cerebrovascular Disorders; Coronary Artery Disease; Creatinine | 2010 |
Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.
Topics: Canada; Cerebrovascular Disorders; Contraindications; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |